1621681-63-7: Cabozantinib N-Oxide
It is one of impurity present in Cabozantinib, Cabozantinib is a tyrosine kinase inhibitor, which inhibits the activity of c-MET vascular endothelial growth factor receptor and other tyrosine kinases, thereby leading to reduced tumor angiogenesis motility and invasiveness. which is used in the treatment of progressive, metastatic medullary thyroid cancer, also indicated for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma.
Additional information on CAS 1621681-63-7
N-[4-[(6, 7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N’-(4-fluorophenyl)-1, 1-cyclopropanedicarboxamide
Schmidinger, M., & Danesi, R. (2017). Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. The Oncologist, 23(3), 306–315. https://doi.org/10.1634/theoncologist.2017-0335
Other products related to cabozantinib
|Name of Impurity||Catalogue No.|